Rational Design of Topographical Helix Mimics as Potent Inhibitors of Protein-Protein Interactions

被引:93
作者
Lao, Brooke Bullock [1 ]
Drew, Kevin [2 ,3 ]
Guarracino, Danielle A. [1 ]
Brewer, Thomas F. [1 ]
Heindel, Daniel W. [1 ]
Bonneau, Richard [2 ,3 ]
Arora, Paramjit S. [1 ]
机构
[1] NYU, Dept Chem, New York, NY 10003 USA
[2] NYU, Dept Biol, New York, NY 10003 USA
[3] NYU, Dept Comp Sci, New York, NY 10003 USA
基金
美国国家科学基金会;
关键词
ALPHA-HELIX; COMPUTATIONAL REDESIGN; P53; PATHWAY; MIMETICS; ANTAGONISTS; IDENTIFICATION; SPECIFICITY; FOLDAMERS; PEPTIDES; BINDING;
D O I
10.1021/ja502310r
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Protein-protein interactions encompass large surface areas, but often a handful of key residues dominate the binding energy landscape. Rationally designed small molecule scaffolds that reproduce the relative positioning and disposition of important binding residues, termed "hotspot residues", have been shown to successfully inhibit specific protein complexes. Although this strategy has led to development of novel synthetic inhibitors of protein complexes, often direct mimicry of natural amino acid residues does not lead to potent inhibitors. Experimental screening of focused compound libraries is used to further optimize inhibitors but the number of possible designs that can be efficiently synthesized and experimentally tested in academic settings is limited. We have applied the principles of computational protein design to optimization of nonpeptidic helix mimics as ligands for protein complexes. We describe the development of computational tools to design helix mimetics from canonical and noncanonical residue libraries and their application to two therapeutically important protein-protein interactions: p53-MDM2 and p300-HIF1 alpha. The overall study provides a streamlined approach for discovering potent peptidomimetic inhibitors of protein-protein interactions.
引用
收藏
页码:7877 / 7888
页数:12
相关论文
共 92 条
[1]   Computational redesign of endonuclease DNA binding and cleavage specificity [J].
Ashworth, Justin ;
Havranek, James J. ;
Duarte, Carlos M. ;
Sussman, Django ;
Monnat, Raymond J., Jr. ;
Stoddard, Barry L. ;
Baker, David .
NATURE, 2006, 441 (7093) :656-659
[2]  
Azzarito V, 2013, NAT CHEM, V5, P161, DOI [10.1038/nchem.1568, 10.1038/NCHEM.1568]
[3]   Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide [J].
Bernal, Federico ;
Tyler, Andrew F. ;
Korsmeyer, Stanley J. ;
Walensky, Loren D. ;
Verdine, Gregory L. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2007, 129 (09) :2456-+
[4]  
Bonetta L, 2010, NATURE, V468, P851, DOI [10.1038/468854a, 10.1038/468852a]
[5]   2,5-Diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency [J].
Borthwick, Alan D. ;
Davies, Dave E. ;
Exall, Anne M. ;
Hatley, Richard J. D. ;
Hughes, Jennifer A. ;
Irving, Wendy R. ;
Livermore, David G. ;
Sollis, Steve L. ;
Nerozzi, Fabrizio ;
Valko, Klara L. ;
Allen, Michael J. ;
Perren, Marion ;
Shabbir, Shalia S. ;
Woollard, Patrick M. ;
Price, Mark A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (14) :4159-4170
[6]   Amphipathic Small Molecules Mimic the Binding Mode and Function of Endogenous Transcription Factors [J].
Buhrlage, Sara J. ;
Bates, Caleb A. ;
Rowe, Steven P. ;
Minter, Aaron R. ;
Brennan, Brian B. ;
Majmudar, Chinmay Y. ;
Wemmer, David E. ;
Al-Hashimi, Hashim ;
Mapp, Anna K. .
ACS CHEMICAL BIOLOGY, 2009, 4 (05) :335-344
[7]   Assessing Helical Protein Interfaces for Inhibitor Design [J].
Bullock, Brooke N. ;
Jochim, Andrea L. ;
Arora, Paramjit S. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2011, 133 (36) :14220-14223
[8]   Computer-based design of novel protein structures [J].
Butterfoss, Glenn L. ;
Kuhlman, Brian .
ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STRUCTURE, 2006, 35 :49-65
[9]   A Preliminary Survey of the Peptoid Folding Landscape [J].
Butterfoss, Glenn L. ;
Renfrew, P. Douglas ;
Kuhlman, Brian ;
Kirshenbaum, Kent ;
Bonneau, Richard .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2009, 131 (46) :16798-16807
[10]   Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy [J].
Chang, Yong S. ;
Graves, Bradford ;
Guerlavais, Vincent ;
Tovar, Christian ;
Packman, Kathryn ;
To, Kwong-Him ;
Olson, Karen A. ;
Kesavan, Kamala ;
Gangurde, Pranoti ;
Mukherjee, Aditi ;
Baker, Theresa ;
Darlak, Krzysztof ;
Elkin, Carl ;
Filipovic, Zoran ;
Qureshi, Farooq Z. ;
Cai, Hongliang ;
Berry, Pamela ;
Feyfant, Eric ;
Shi, Xiangguo E. ;
Horstick, James ;
Annis, D. Allen ;
Manning, Anthony M. ;
Fotouhi, Nader ;
Nash, Huw ;
Vassilev, Lyubomir T. ;
Sawyer, Tomi K. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (36) :E3445-E3454